Piramal Pharma Limited · NSE:PPLPHARMA
Piramal Pharma — Q4 FY2024 Earnings Presentation
28 slides from Piramal Pharma's earnings presentation, May 2024
Slide 1: Piramal Pharma Limited Q4 & FY2024 Results
Piramal Pharma Limited – Q4 & FY2024 Results Presentation Piramal Pharma Limited Q4 & FY2024 Results May 2024
Slide 2: Disclaimer
Piramal Pharma Limited – Q4 & FY2024 Results Presentation Page 2 Disclaimer This presentation and the accompanying slides (the “Presentation”), which have been prepared by Piramal Pharma Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, reco
Slide 3: Q4 FY2024 – Ending the Financial Year on a Strong Note
Piramal Pharma Limited – Q4 & FY2024 Results Presentation Page 3 Q4 FY2024 – Ending the Financial Year on a Strong Note Revenue from Operations EBITDA Margins Adjusted Net Profit After Tax (In INR Crore) (In INR Crore) PAT before Exceptional Exceptional Item Item 2,552 22% 2,164 17% 132 31 50 101 50
Slide 4: FY2024 – A Resilient Performance Amidst Challenging Environment
Piramal Pharma Limited – Q4 & FY2024 Results Presentation Page 4 FY2024 – A Resilient Performance Amidst Challenging Environment Revenue from Operations EBITDA Margins Net Debt / EBITDA Ratio (In INR Crore) 8,171 19% 17% 5.6 7,082 5.0 12% 6,559 3.7 3.4 2.9 FY22 FY23 FY24 FY22 FY23 FY24 Q4FY23 Q1FY24
Slide 5: Global Footprint with a Diversified Revenue Base
Piramal Pharma Limited – Q4 & FY2024 Results Presentation Page 5 Global Footprint with a Diversified Revenue Base 17 100+ ~500 6,000+ Manufacturing and Countries Countrieswith with CDMO Customers CHG Customers (Hospitals) development Sites Commercial commercialPresence presence Total FY24 Revenue by
Slide 6: Business-wise Performance
Piramal Pharma Limited – Q4 & FY2024 Results Presentation Page 6 Business-wise Performance
Slide 7: Contract Development and Manufacturing Organization Business
Piramal Pharma Limited – Q4 & FY2024 Results Presentation Page 7 Contract Development and Manufacturing Organization Business Performance Highlights Revenue performance in Q4 FY2024 (In INR Crore) Strong recovery in FY2024 driven by: • Strong order inflows, despite a challenging biotech funding en
Slide 8: Deep Pipeline of Development Projects across Multiple Phases
Piramal Pharma Limited – Q4 & FY2024 Results Presentation Page 8 Deep Pipeline of Development Projects across Multiple Phases Revenue by services Building molecule pipeline across clinical phases since FY17 Strengthened molecule pipeline across clinical phases since FY17 Pre-clinical, 12% 4% Phase I
Slide 9: Diversified Blue Chip Customer Base
Piramal Pharma Limited – Q4 & FY2024 Results Presentation Page 9 Diversified Blue Chip Customer Base We have an Attractive Customer Mix… … with Relatively Low Revenue Concentration We have an Attractive Customer Mix… … with Low Revenue Concentration FY24 Revenue #1 11% #2 Generics Big 8% 29% Pharma
Slide 10: Growth in Revenue and Contribution from Differentiated Offerings
Piramal Pharma Limited – Q4 & FY2024 Results Presentation Page 10 Growth in Revenue and Contribution from Differentiated Offerings Revenue ($ mn) from Revenue ($ mn) from Differentiated Contribution Contribution of Differentiated of Differentiated Offerings to Differentiated OfferingsOfferings Offer
Slide 11: Leveraging Global Network of Sites to Offer Integrated Services
Piramal Pharma Limited – Q4 & FY2024 Results Presentation Page 11 Leveraging Global Network of Sites to Offer Integrated Services Benefits of the Integrated Platform Integrated project involves more than one site Integrated Projects Cross Selling Built a platform for Integrated Service offerings
Slide 12: Continue to Maintain Best-in-Class Quality Track Record
Piramal Pharma Limited – Q4 & FY2024 Results Presentation Page 12 Continue to Maintain Best-in-Class Quality Track Record 300+ Regulatory Inspections# since FY12 with zero OAI* ~150 audits annually by customers USFDA Inspections 44 Customer Audits Total Regulatory Inspections 35 36 36 29 29 197 26 2
Slide 13: Complex Hospital Generics Business
Piramal Pharma Limited – Q4 & FY2024 Results Presentation Page 13 Complex Hospital Generics Business Performance Highlights Revenue growth in Q4 FY2024 (In INR Crore) YoY revenue growth in FY2024 driven by: 702 667 • Healthy volume growth in the inhalation anesthesia (IA) in the US and ROW markets
Slide 14: CHG Revenues by Product Segment and Geography
Piramal Pharma Limited – Q4 & FY2024 Results Presentation Page 14 CHG Revenues by Product Segment and Geography Revenue by product segment Revenue by geography % FY24 CHG Revenue Inhalation Anesthesia Intrathecal Therapy (67%) (15%) Others 23% US 51% India FY24 CHG 6% Revenue Japan Injectable Anesth
Slide 15: Consolidating our Position Amongst Top 4 Inhalation Anesthesia Players in the World
Piramal Pharma Limited – Q4 & FY2024 Results Presentation Page 15 Consolidating our Position Amongst Top 4 Inhalation Anesthesia Players in the World Global Inhalation Anesthesia Market Global IA market comprising of Sevoflurane, Isoflurane and Desflurane is about $1.04bn* China (27% market shar
Slide 16: India Consumer Healthcare Business
Piramal Pharma Limited – Q4 & FY2024 Results Presentation Page 16 India Consumer Healthcare Business Performance Highlights Revenue growth Revenue growth in in Q4 Q4FY2024 FY2024 (In INR Crore) New Product launches - 27 new products and 24 new SKUs launched in FY24 238 210 Q4FY23 Q4FY24 Power Br
Slide 17: Focus on Power Brands with Continuous Investments in Brand Promotion and Marketing
Piramal Pharma Limited – Q4 & FY2024 Results Presentation Page 17 Focus on Power Brands with Continuous Investments in Brand Promotion and Marketing Little’s Lacto Calamine Tetmosol i-Range Polycrol Wipes, Toys, Diapers, Oil Control Lotion, Medicated Soap, Cream Contraceptive Pill, Ovulation Antacid
Slide 18: New Product Launches – An Important Driver of Growth
Piramal Pharma Limited – Q4 & FY2024 Results Presentation Page 18 New Product Launches – An Important Driver of Growth Regular new product launches contributing to growth New product and SKUs launches CIR (Adult Hygiene Range) received encouraging response in the first year of National launch 63 51
Slide 19: Multi-channel Distribution Network and Tech-enabled Sales Coverage
Piramal Pharma Limited – Q4 & FY2024 Results Presentation Page 19 Multi-channel Distribution Network and Tech-enabled Sales Coverage Presence across traditional and alternate trade channels Wide coverage across Strengthening presence in Expanding presence on Direct-to-Customer (D2C) general trade an
Slide 20: Abbvie Therapeutics India Private Limited
Piramal Pharma Limited – Q4 & FY2024 Results Presentation Page 20 Abbvie Therapeutics India Private Limited* Joint Venture Arrangement Ownership Ownership 49% 51% In FY2024, the JV reported# revenue of Rs.461Cr with PAT margin of 26% Continue to be one of 400+ Strong presence in Key Brands the marke
Slide 21: Sustainability Initiatives
Piramal Pharma Limited – Q4 & FY2024 Results Presentation Page 21 Sustainability Initiatives
Slide 22: Key Sustainability Highlights for the Year
Piramal Pharma Limited – Q4 & FY2024 Results Presentation Page 22 Key Sustainability Highlights for the Year Climate Change Management Taken a target for 42% reduction in our Scope 1 and Scope 2 GHG emissions by FY2030 (baseline of FY2022). This is in-line with the SBTI’s# pathway to limit global wa
Slide 23: Key Sustainability Highlights for the Year
Piramal Pharma Limited – Q4 & FY2024 Results Presentation Page 23 Key Sustainability Highlights for the Year Diversity & Inclusion Third Party Assessment Community Development Women in global Score 55 - Significant workforce increased to improvement over over 17% last year ET Now’s Best Women repres
Slide 24: Financials
Piramal Pharma Limited – Q4 & FY2024 Results Presentation Page 24 Financials
Slide 25: Consolidated Financials Highlights – Profit & Loss Statement
Piramal Pharma Limited – Q4 & FY2024 Results Presentation Page 25 Consolidated Financials Highlights – Profit & Loss Statement (In INR Crores or as stated) Quarterly Performance Annual Performance Particulars Q4 FY2024 Q4 FY2023 YoY Change FY2024 FY2023 YoY Change Revenue from Operations* 2,552 2,16
Slide 26: Consolidated Financials Highlights – Balance Sheet
Piramal Pharma Limited – Q4 & FY2024 Results Presentation Page 26 Consolidated Financials Highlights – Balance Sheet (In INR Crores) Key Balance Sheet Items As on 31-Mar-24 As on 31-Mar-23 Total Equity 7,911 6,774 Net Debt 3,932 4,781 Total 11,843 11,555 Net Fixed Assets 9,106 8,887 Tangible Assets
Slide 27: Dial-in details for Q4 and FY2024 Earnings Conference Call
Piramal Pharma Limited – Q4 & FY2024 Results Presentation Page 27 Dial-in details for Q4 and FY2024 Earnings Conference Call Event Location & Time Telephone Number +91 22 6280 1461 / +91 22 7115 8320 (Primary Number) India – 09:30 AM IST 1 800 120 1221 (Toll free number) USA – 12:00 AM Toll free num
Slide 28: For Investor Queries
Piramal Pharma Limited – Q4 & FY2024 Results Presentation Page 28 For Investor Queries: Gagan Borana Investor Relations & Enterprise Risk Management Email : gagan.borana@piramal.com Phone : +91 22 3802 3090